Reiteration of Risks Associated with the Use of Favipiravir
The Department of Health (DOH) in the Philippines issued Department Circular No. 2020-0294 on July 9, 2020, reiterating the risks associated with the use of Favipiravir as outlined in the FDA Advisory No. 2020-1038. The circular emphasizes the drug's teratogenic and embryotoxic effects observed in animal studies, urging healthcare providers to exercise caution when prescribing it. Physicians are instructed to inform patients of these risks and to monitor for adverse effects closely. Additionally, all adverse drug reactions should be reported to the FDA, with guidance provided for the reporting process.
Law Information
- Reference Number
- DOH Department Circular No. 2020-0294
- Date Enacted
- Subcategory
- Department of Health
- Jurisdiction
- Philippines
- Enacting Body
- Congress of the Philippines
Full Law Text
July 9, 2020
DOH DEPARTMENT CIRCULAR NO. 2020-0294
| TO | : | All Undersecretaries and Assistant Secretaries; Directors of Bureaus and Centers for Health Development; Minister of Health — Bangsamoro Autonomous Region in Muslim Mindanao); Executive Directors of Specialty Hospitals and National Nutrition Council: Chiefs of Medical Centers, Hospitals, Sanitaria and Institutes; President of the Philippine Health Insurance Corporation; Directors of Philippine National Aids Council and Treatment and Rehabilitation Centers, and All Others Concerned |
| SUBJECT | : | Reiteration of Risks Associated with the Use of Favipiravir |
The Department of Health hereby reiterates the risks associated with the use of Favipiravir as specified by the Food and Drug Administration (FDA) Advisory No. 2020-1038 on the "Risks Associated with the Use of Favipiravir" as attached.
This is to remind all hospitals and healthcare providers to take extreme caution on the use of Favipiravir due to its teratogenic and embryotoxic effects in animal studies. Physicians are also advised to explain fully to their patients the risks associated with the drug and to carefully monitor patients for other possible adverse effects.
All are enjoined to report adverse drug reactions (ADR) to FDA through this link: https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH ad fill out all the required fields. All hospitals with VigiFlow accounts are encouraged to report in the said platform. For inquiries email us at [email protected]
Dissemination of the information to all concerned is requested.
By Authority of the Secretary of Health
(SGD.) MARIA ROSARIO SINGH-VERGEIRE, MD, MPH, CESO IVOIC-Undersecretary of Health
ATTACHMENT
FDA Advisory No. 2020-1038
Cite This Law
Reiteration of Risks Associated with the Use of Favipiravir, DOH Department Circular No. 2020-0294, Jul 9, 2020 (Philippines)
Reiteration of Risks Associated with the Use of Favipiravir, DOH Department Circular No. 2020-0294 (Phil. 2020)
Related Laws
- Risks Associated with the Use of FavipiravirFDA Advisory No. 1038-20 • Jun 5, 2020 • Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) Issuances
- Reiteration of Advisory on Work Arrangements in the Department of Education in Light of Recent Developments in the COVID-19 SituationDepEd Memorandum No. 054-20 • May 29, 2020 • Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) Issuances
- Reiteration of the Courts' Compliance with the eSubpoena SystemOCA Circular No. 82-2019 • Jun 13, 2019 • Supreme Court Issuances
- Reiteration of the Directive in OCA Circular No. 127-2021 Dated 13 October 2021 (Re: Prioritization of Cases and Use of Alternative Dispute Resolution)OCA Circular No. 37-2022 • Feb 17, 2022 • Supreme Court Issuances
- Reiteration of the Directive in OCA Circular No. 173-2017 Dated 17 August 2017 (Proper Use of Social Media)OCA Circular No. 58-2022 • Mar 18, 2022 • Supreme Court Issuances
- Reiteration of Strict Observance with All Health and Safety Protocols Against COVID-19OCA Circular No. 93-2022 • Apr 25, 2022 • Supreme Court Issuances
Browse More Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) Issuances
Explore other laws in the Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) Issuances category.
View All Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) IssuancesNeed Help Understanding This Law?
Ask our AI assistant to explain provisions, implications, or related laws.
Ask AI About This Law